I think that part of the change-in-name was to draw a line in the sand. It is the coupling with PMOs that is the definitive development. Sarepta have been somewhat hamstrung by its delivery system in building a portfolio of RNA therapeutics but PYC has the opportunity to forge ahead. Mind you hamstrung is loosely used in the context of Sarepta having acquired a US$8B market cap.
Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-15
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.000(0.00%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 09.11am 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable